MDxHealth is trading at $0.14, down 5.75%, with no specific cause established for the November 5 decline.
- No new MDxHealth announcement explaining the decline surfaced in available reporting.
- The company previously said preliminary Q3 revenue was about $22.7 million, below expectations, and suspended its $110–115 million full-year revenue guidance. Full results are scheduled for November 12.
- Healthcare was rising in the supplied sector context, so it does not explain the drop.